Clinical Trials at Swedish Cancer Institute
As of August 2026, 37 paid clinical trials are recruiting at Swedish Cancer Institute, located at 1221 MADISON ST, STE 150, SEATTLE, WA 98104-3588, phone (206) 215-6487 in Seattle, Washington. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Colorectal Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
37 clinical trials at Swedish Cancer Institute
·Clear filters·A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Selinexor and Backbone Treatments of Multiple Myeloma Patients
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Minimally Invasive Esophagectomy Pain Control Trial
Early Chest Tube Removal After Surgery for Primary Spontaneous Pneumothorax: A Randomized Controlled Trial
Common conditions studied in Seattle
- Acute Myeloid Leukemia (34 active studies)
- Breast Cancer (20 active studies)
- Colorectal Cancer (19 active studies)
- Ovarian Cancer (16 active studies)
- Multiple Myeloma (15 active studies)
- Prostate Cancer (14 active studies)
Leading research sponsors in Seattle
- University of Washington
- Fred Hutchinson Cancer Center
- National Cancer Institute (NCI)
- Seattle Children's Hospital
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Seattle?
There are approximately 1,282 recruiting clinical trials in Seattle, Washington listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Seattle pay participants?
Most recruiting trials in Seattle compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Seattle?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Seattle?
The most common conditions under active study in Seattle include Acute Myeloid Leukemia (34), Breast Cancer (20), Colorectal Cancer (19), Ovarian Cancer (16), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Seattle?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Seattle on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Seattle?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Seattle?
Recruiting research sites in Seattle include Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Seattle right now?
The largest active categories in Seattle are Cancer & tumors (493), Neurology & pain (64), Diabetes & metabolic (60). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Swedish Cancer Institute?
Swedish Cancer Institute is located at 1221 MADISON ST, STE 150, SEATTLE, WA 98104-3588. Use the Google Maps link in the intro above to get directions.
How do I contact Swedish Cancer Institute?
You can reach Swedish Cancer Institute by phone at (206) 215-6487. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.